title: Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sites.
abstract: OBJECTIVE
  In response to widespread pertussis outbreaks and infant deaths, in 2010, the California Department of Health (CDPH) and in 2011 the Advisory Committee on Immunization Practices (ACIP) advised that the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine be administered during pregnancy. The goals of this study were to describe Tdap coverage among pregnant women following these recommendations.
  
  
  METHODS
  In this observational cohort study, we utilized electronic medical record and claims data from seven Vaccine Safety Datalink sites to identify pregnancies and Tdap administrations. All Tdap doses were classified as pre-pregnancy, during pregnancy or post-pregnancy/postpartum. For pregnancies ending in a live birth, we evaluated factors associated with Tdap vaccination.
  
  
  RESULTS
  Among 289,141 live births at the California VSD sites, receipt of Tdap during pregnancy increased substantially in the years 2010, 2011, and 2012, when coverage was 15.9, 30.0 and 19.5%, respectively. Among 82,398 women with live births at the Oregon, Washington, Colorado, Wisconsin and Minnesota VSD sites, receipt of Tdap during pregnancy first increased in 2012, at 16.0%. Women receiving early prenatal care and other vaccine(s) during pregnancy had higher Tdap coverage.
  
  
  CONCLUSIONS
  We observed substantial increases in Tdap coverage during pregnancy following CDPH and ACIP recommendations.
authors: HealthPartners Institute for Education and Research, Minneapolis, MN, United States. Electronic address: Elyse.o.kharbanda@healthpartners.com.
authors: Elyse O
authors: EO
authors: Kharbanda
authors: HealthPartners Institute for Education and Research, Minneapolis, MN, United States.
authors: Gabriela
authors: G
authors: Vazquez-Benitez
authors: Department of Obstetrics and Gynecology, Yale University, New Haven, CT, United States.
authors: Heather
authors: H
authors: Lipkind
authors: Center for Health Research, Kaiser Permanente Northwest, Portland, OR, United States.
authors: Allison L
authors: AL
authors: Naleway
authors: Vaccine Study Center, Kaiser Permanente of Northern California, Oakland, CA, United States.
authors: Nicola P
authors: NP
authors: Klein
authors: Kaiser Permanente of Southern California, Pasadena, CA, United States.
authors: T Craig
authors: TC
authors: Cheetham
authors: Kaiser Permanente Institute for Health Research, Denver, CO, United States; Denver Health Community Health Services, Denver, United States.
authors: Simon J
authors: SJ
authors: Hambidge
authors: Immunization Safety Office, Division of Healthcare Quality and Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States.
authors: Claudia
authors: C
authors: Vellozzi
authors: HealthPartners Institute for Education and Research, Minneapolis, MN, United States.
authors: James D
authors: JD
authors: Nordin
mesh_terms: D000293:Adolescent; D000328:Adult; D015331:Cohort Studies; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D005260:Female; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D011256:Pregnancy Outcome; D013745:Tetanus Toxoid; D014481:United States; D014611:Vaccination / Q000706:statistics & numerical data*; D014917:Whooping Cough / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D013745:Tetanus Toxoid
keywords: Pertussis; Pregnancy; Vaccine coverage